DK1289985T3 - Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer - Google Patents

Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer

Info

Publication number
DK1289985T3
DK1289985T3 DK01935038T DK01935038T DK1289985T3 DK 1289985 T3 DK1289985 T3 DK 1289985T3 DK 01935038 T DK01935038 T DK 01935038T DK 01935038 T DK01935038 T DK 01935038T DK 1289985 T3 DK1289985 T3 DK 1289985T3
Authority
DK
Denmark
Prior art keywords
beta
phosphodiesterase inhibitors
derivatives useful
carboline derivatives
carboline
Prior art date
Application number
DK01935038T
Other languages
Danish (da)
English (en)
Inventor
Zhihua Sui
Mark J Macielag
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of DK1289985T3 publication Critical patent/DK1289985T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK01935038T 2000-05-17 2001-05-03 Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer DK1289985T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20466700P 2000-05-17 2000-05-17
PCT/US2001/014357 WO2001087038A2 (en) 2000-05-17 2001-05-03 β-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE

Publications (1)

Publication Number Publication Date
DK1289985T3 true DK1289985T3 (da) 2004-04-05

Family

ID=22758909

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01935038T DK1289985T3 (da) 2000-05-17 2001-05-03 Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer

Country Status (32)

Country Link
US (2) US6492358B2 (pl)
EP (1) EP1289985B1 (pl)
JP (1) JP5014551B2 (pl)
KR (1) KR20030031482A (pl)
CN (1) CN1255403C (pl)
AR (1) AR028576A1 (pl)
AT (1) ATE256127T1 (pl)
AU (2) AU6116701A (pl)
BG (1) BG66141B1 (pl)
CA (1) CA2409715C (pl)
CZ (1) CZ20023934A3 (pl)
DE (1) DE60101479T2 (pl)
DK (1) DK1289985T3 (pl)
ES (1) ES2211806T3 (pl)
GE (1) GEP20053511B (pl)
HK (1) HK1051368A1 (pl)
HR (1) HRP20020910B1 (pl)
HU (1) HUP0302412A3 (pl)
IL (2) IL152873A0 (pl)
MX (1) MXPA02011426A (pl)
MY (1) MY128479A (pl)
NO (1) NO324251B1 (pl)
NZ (1) NZ522731A (pl)
PL (1) PL205507B1 (pl)
PT (1) PT1289985E (pl)
RU (1) RU2271358C2 (pl)
SK (1) SK16972002A3 (pl)
TR (1) TR200302309T4 (pl)
TW (1) TWI286553B (pl)
UA (1) UA74826C2 (pl)
WO (1) WO2001087038A2 (pl)
ZA (1) ZA200210111B (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062339A1 (en) * 2000-12-08 2002-08-15 Smithkline Beecham Corporation Antibacterial compounds
US6900220B2 (en) * 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
WO2002064590A2 (en) * 2001-02-12 2002-08-22 Lilly Icos Llc Carboline derivatives
DE60216233T2 (de) * 2001-02-12 2007-09-27 Lilly Icos Llc, Wilmington Carbolinderivate
MXPA03009750A (es) * 2001-04-25 2004-06-30 Lilly Icos Llc Compuestos quimicos.
WO2002098875A1 (en) * 2001-06-05 2002-12-12 Lilly Icos Llc Carboline derivatives as pde-5 inhibitors
ATE335742T1 (de) 2001-06-21 2006-09-15 Lilly Icos Llc Carbolinderivate als pdev inhibitoren
CA2467269C (en) 2001-11-14 2011-04-05 Weiqin Jiang Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
BRPI0307699A2 (pt) * 2002-02-07 2015-06-16 Gtx Inc Tratamento de hiperplasia benigna da próstata com sarms.
CA2490239C (en) * 2002-06-19 2011-05-24 Janssen Pharmaceutica N.V. Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
WO2004113300A1 (ja) * 2003-06-23 2004-12-29 Ono Pharmaceutical Co., Ltd. 新規三環性複素環化合物
CN1910183A (zh) 2004-01-23 2007-02-07 希龙公司 四氢咔啉化合物作为抗癌药
UA92317C2 (ru) * 2004-03-15 2010-10-25 Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. Производные карболина, пригодные для ингибирования развития кровеносных сосудов
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
EP1829874B1 (en) * 2004-12-22 2014-02-12 Ono Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
GB2422828A (en) * 2005-02-03 2006-08-09 Hunter Fleming Ltd Tricyclic cytoprotective compounds comprising an indole residue
JP2009502961A (ja) * 2005-07-29 2009-01-29 コンサート ファーマシューティカルズ インコーポレイテッド 新規な医薬組成物
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007292848A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2178537A4 (en) * 2007-07-19 2011-08-17 Merck Sharp & Dohme BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS
EP2225250A2 (en) 2007-11-30 2010-09-08 Biota Scientific Management Pty Ltd Bicyclic ppat inhibitors as antibacterial agents
MX2010007430A (es) 2008-01-11 2010-12-21 Albany Molecular Res Inc Piridoindoles (1-azinona)-sustituidos como antagonistas de la hormona de concentracion melanina humana.
CL2009000724A1 (es) 2008-03-24 2009-05-29 Medivation Technologies Inc Compuestos derivados de 1,2,3,4-tetrahidro-pirido[3,4-b]indol, moduladores del receptor de histamina, serotonina y dopamina; composicion farmaceutica; kit farmaceutico; y uso para tratar un trastorno cognitivo, psicotico, mediado por neurotransmisores y/o neurologico.
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2010107485A1 (en) * 2009-03-17 2010-09-23 The Trustees Of Columbia University In The City Of New York E3 ligase inhibitors
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US8637501B2 (en) 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
EP2480079A4 (en) * 2009-09-23 2015-04-08 Medivation Technologies Inc PYRIDO- (3,4-B-) INDOLE AND USE METHOD THEREFOR
PT2592081T (pt) * 2010-07-06 2017-05-03 Ono Pharmaceutical Co Derivado de tetrahidrocarbolina
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
TW201309698A (zh) 2011-03-18 2013-03-01 Ono Pharmaceutical Co 四氫咔啉衍生物
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN107216327A (zh) * 2017-06-27 2017-09-29 山东大学 5型磷酸二酯酶抑制剂及其制备方法和用途
WO2021046194A1 (en) * 2019-09-03 2021-03-11 The Regents Of The University Of Colorado A Body Corporate Tryptoline-based benzothiazoles and their use as antibiotics and antibiotic resistance-modifying agents
EP4011877A3 (en) * 2020-12-11 2023-01-11 Institut de Cardiologie de Montréal Method of treating elevated plasma cholesterol
EP4267578A1 (en) 2020-12-23 2023-11-01 Recurium IP Holdings, LLC Estrogen receptor modulators

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1055203A (en) 1964-09-16 1967-01-18 Ici Ltd -ß-carboline derivatives, a process for their manufacture, and compositions containing them
US4228168A (en) 1978-11-22 1980-10-14 Tanabe Seiyaku Co., Ltd. Azepino [1,2,3-lm]-β-carboline compounds and pharmaceutical composition thereof
NZ194747A (en) 1979-08-29 1988-11-29 Schering Ag 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives
WO1988002751A1 (en) 1986-10-13 1988-04-21 Asahi Kasei Kogyo Kabushiki Kaisha Pyridine derivatives
CS262100B1 (cs) * 1987-07-17 1989-02-10 Protiva Miroslav 1-substituované 2- [ (4-methyl-l-piperazinyl)acetyl ] -2,3,4,9- -tetrahydro-lH-pyrido( 3,4-b)indoly a jejich hydrochloridy
ATE136032T1 (de) 1987-07-20 1996-04-15 Duphar Int Res 8,9-anellierte 1,2,3,4-tetrahydro-beta-carbolin- derivate
FR2619112B1 (fr) * 1987-08-07 1989-11-17 Synthelabo Derives de (piperidinyl-4)methyl-2 benzo(b)furo(2,3-c) pyridines, leur preparation et leur application en therapeutique
US4971974A (en) 1988-06-16 1990-11-20 Neurex Corporation Benzothiophenes as appetite suppressants
EP0386258A4 (en) 1988-08-11 1992-05-13 Asahi Kasei Kogyo Kabushiki Kaisha Tetrahydropyridine derivatives
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
FR2663935A1 (fr) 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
EP0705832B1 (en) * 1994-09-12 2003-08-13 Eli Lilly And Company Limited Serotonergic modulators
FR2724384B1 (fr) 1994-09-14 1999-04-16 Cemaf Nouveaux derives de la 3,4-dihydro beta-carboline agonistes de la melatonine, leur procede de preparation et leur utilisation a titre de medicament
DE4436190A1 (de) 1994-10-10 1996-04-11 Gerhard Prof Dr Bringmann Halogenierte ß-Carbolin-Derivate, Verfahren zu ihrer Herstellung und Verwendung dieser Substanzen zur Hemmung der Atmungskette
DE4436509A1 (de) 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5968910A (en) * 1994-11-30 1999-10-19 Jan M. R. Balzarini Compositions containing two or three inhibitors of different HIV reverse transcriptases
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
FR2748026B1 (fr) 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TR199802282T2 (xx) 1996-05-10 1999-03-22 Icos Corporation Karbolin t�revleri.
CA2256889A1 (en) 1996-05-31 1997-12-04 Mochida Pharmaceutical Co., Ltd. Pyridocarbazole derivatives having cgmp-pde inhibitory effect
WO1998040385A1 (en) 1997-03-07 1998-09-17 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
WO2000002878A1 (en) 1998-07-11 2000-01-20 University Of Bristol Compounds having activity at imidazoline receptors
FR2796644B1 (fr) * 1999-07-23 2001-09-07 Adir Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
EP1289985A2 (en) 2003-03-12
MXPA02011426A (es) 2004-09-06
BG66141B1 (bg) 2011-07-29
CA2409715A1 (en) 2001-11-22
IL152873A0 (en) 2003-06-24
SK16972002A3 (sk) 2003-11-04
US20020010189A1 (en) 2002-01-24
ATE256127T1 (de) 2003-12-15
AU2001261167B2 (en) 2006-10-05
PL365445A1 (pl) 2005-01-10
CN1255403C (zh) 2006-05-10
DE60101479D1 (en) 2004-01-22
ES2211806T3 (es) 2004-07-16
PT1289985E (pt) 2004-03-31
CN1446217A (zh) 2003-10-01
WO2001087038A2 (en) 2001-11-22
UA74826C2 (en) 2006-02-15
US6864253B2 (en) 2005-03-08
PL205507B1 (pl) 2010-04-30
MY128479A (en) 2007-02-28
HUP0302412A3 (en) 2007-02-28
NO20025527L (no) 2003-01-16
HRP20020910B1 (en) 2011-02-28
EP1289985B1 (en) 2003-12-10
AU6116701A (en) 2001-11-26
JP5014551B2 (ja) 2012-08-29
GEP20053511B (en) 2005-05-10
NZ522731A (en) 2004-09-24
IL152873A (en) 2012-01-31
HK1051368A1 (en) 2003-08-01
WO2001087038A3 (en) 2002-05-16
NO20025527D0 (no) 2002-11-18
NO324251B1 (no) 2007-09-17
HUP0302412A2 (hu) 2003-11-28
DE60101479T2 (de) 2005-04-28
ZA200210111B (en) 2004-03-12
JP2003533453A (ja) 2003-11-11
HRP20020910A2 (en) 2004-12-31
AR028576A1 (es) 2003-05-14
RU2271358C2 (ru) 2006-03-10
TWI286553B (en) 2007-09-11
TR200302309T4 (tr) 2004-02-23
KR20030031482A (ko) 2003-04-21
BG107285A (bg) 2003-07-31
US20030166641A1 (en) 2003-09-04
CA2409715C (en) 2010-09-14
CZ20023934A3 (cs) 2003-10-15
US6492358B2 (en) 2002-12-10

Similar Documents

Publication Publication Date Title
DK1289985T3 (da) Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
NO20030055L (no) Colchinolderivater som angiogenese inhibitorer
NO20021239L (no) Pteridinoner som kinase-inhibitorer
DK1944305T3 (da) Quinolinderivater som phosphodiesteraseinhibitorer
NO20030867D0 (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
ATE278690T1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
NO20043174L (no) Pyrido[2,1-a]isokinolinderivater som DPP-IV inhibitorer
DK1268480T3 (da) 8-Quinolinxanthin- og 8-isoquinolinxanthinderivater som PDE5-inhibitorer
NO20015065D0 (no) Pyrazolobenzodiazepiner som CDK2-inhibitorer
DK1226143T3 (da) Imidazopyridinderivater som phosphodiesterase VII-inhibitorer
NO20033618L (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
NO20022125D0 (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
DK1534707T5 (da) Substituerede 2,4-dihydropyrrolo[3,4-b]quinolin-9-on-derivater egnede som phosphodiesteraseinhibitorer
NO20021959L (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20022123D0 (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer
NO20035206D0 (no) Pyrimidin-derivater anvendelige som selektive COX-2- inhibitorer
DK1296981T3 (da) Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer
DE50104434D1 (de) Lactam-substituierte pyrazolopyridinderivate
SI1289985T1 (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase